18558765. INDANONE AND TETRALONEKETO OR HYDROXYL OXIMES AS CANCEL THERAPEUTICS simplified abstract (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM)

INDANONE AND TETRALONEKETO OR HYDROXYL OXIMES AS CANCEL THERAPEUTICS

Organization Name

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor(s)

Stanton Mchardy of San Antonio TX (US)

Michael W. Tidwell of San Antonio TX (US)

Andrew J. Brenner of San Antonio TX (US)

Ratna K. Vadlamudi of San Antonio TX (US)

INDANONE AND TETRALONEKETO OR HYDROXYL OXIMES AS CANCEL THERAPEUTICS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18558765 titled 'INDANONE AND TETRALONEKETO OR HYDROXYL OXIMES AS CANCEL THERAPEUTICS

The abstract of this patent application describes compounds, salts, stereoisomers, and prodrugs that are ER ligands, with a focus on ERβ selectivity and specificity.

• These compounds are designed to target specific estrogen receptors, providing potential therapeutic benefits.
• The innovation lies in the development of compounds that selectively target ERβ, which could lead to more effective treatments with fewer side effects.
• The patent covers a range of compounds and their derivatives that show promise as ER ligands for various applications.

Potential Applications: - Treatment of hormone-related conditions such as breast cancer or osteoporosis - Development of new pharmaceuticals targeting estrogen receptors

Problems Solved: - Addressing the need for more selective and effective estrogen receptor modulators - Improving the treatment options for hormone-related diseases

Benefits: - Enhanced therapeutic efficacy with reduced side effects - Potential for personalized medicine based on estrogen receptor profiles

Commercial Applications: Title: "Innovative ER Ligands for Targeted Therapies in Hormone-Related Diseases" This technology could have significant implications in the pharmaceutical industry, leading to the development of novel treatments for hormone-related conditions.

Questions about ER Ligands: 1. How do ER ligands differ from traditional hormone therapies?

  ER ligands target specific estrogen receptors, providing more targeted effects compared to broad-spectrum hormone therapies.

2. What potential challenges could arise in the development of ERβ-selective ligands?

  Developing compounds that are both selective and effective can be a complex process, requiring careful optimization and testing.

Original Abstract Submitted

Certain embodiments are directed to compounds, pharmaceutically acceptable salts, stereoisomers and prodrugs thereof, that are ER ligands and particularly to such compounds that are ERβ selective and/or ERβ specific ligands.